Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05455320
What this trial is testing

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 864
Testing effectiveness (Phase 2)Looking for participantsNCT05521802
What this trial is testing

C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai AbelZeta Ltd. 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT04883242
What this trial is testing

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 30
Early research (Phase 1)Study completedNCT00642954
What this trial is testing

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Merck Sharp & Dohme LLC 31
Testing effectiveness (Phase 2)Study completedNCT06212596
What this trial is testing

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
University of Leeds 66
Testing effectiveness (Phase 2)Study completedNCT02410694
What this trial is testing

Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie 90
Early research (Phase 1)Study completedNCT03288480
What this trial is testing

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Promontory Therapeutics Inc. 24
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)Study completedNCT02992483
What this trial is testing

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Novartis Pharmaceuticals 31
Testing effectiveness (Phase 2)Study completedNCT01745588
What this trial is testing

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 23
Early research (Phase 1)Study completedNCT00723359
What this trial is testing

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Biotest Pharmaceuticals Corporation 32
Early research (Phase 1)Active Not RecruitingNCT05675449
What this trial is testing

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 59
Early research (Phase 1)Study completedNCT01456689
What this trial is testing

Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 79
Testing effectiveness (Phase 2)Study completedNCT03544281
What this trial is testing

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 153
Early research (Phase 1)Ended earlyNCT00963495
What this trial is testing

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 11
Testing effectiveness (Phase 2)Study completedNCT00315757
What this trial is testing

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Human Genome Sciences Inc. 105
Early research (Phase 1)UnknownNCT04706936
What this trial is testing

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Second Affiliated Hospital, Zhejiang University, School of Medicine 25
Early research (Phase 1)Ended earlyNCT00243763
What this trial is testing

TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis 64
Large-scale testing (Phase 3)Looking for participantsNCT05519085
What this trial is testing

Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene 810
Very early researchLooking for participantsNCT06045091
What this trial is testing

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Hrain Biotechnology Co., Ltd. 18
Next Page